Every Form 4 that Profusa, Inc. (PFSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PFSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFSA filings page.
Profusa, Inc. (PFSA) reports that Chief Financial Officer Fred S. Knechtel had his ownership restructured on August 21, 2026 through entity transactions. He acquired 54,323 shares of common stock directly via a pro rata distribution from NorthView Sponsor I LLC and no price was paid.
The filing also shows the disposition of 301,991 indirectly held shares previously held through NorthView Sponsor I LLC, which distributed all its Profusa shares to its members. After these transactions, Knechtel directly holds 54,470 shares of Profusa common stock, including 147 shares he already held, and no Rule 10b5-1 trading plan is reported.
Profusa, Inc. (PFSA) reported that Chief Executive Officer Jack E. Stover restructured his holdings in the company’s common stock on August 21, 2026. He received 32,018 shares directly through a pro rata distribution from NorthView Sponsor I LLC, bringing his direct holdings to 32,091 shares, including 73 shares already held. On the same date, 301,991 indirectly held shares attributed to NorthView Sponsor I LLC were distributed to its members, leaving no remaining indirect holdings for Stover through that LLC. The filing notes that Stover is a manager of the LLC and may be deemed to share beneficial ownership of its securities but disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Profusa, Inc. (PFSA) reports that Chief Financial Officer Fred S. Knechtel, through NorthView Sponsor I LLC, converted a portion of a Convertible Promissory Note into Common Stock on August 12, 2026. The conversion turned $1,292,521 principal of the note into 1,207,964 shares of Common Stock, which became 301,991 shares after a 1‑for‑4 reverse stock split, at an effective post-split conversion price of $4.28 per share (equivalent to $1.07 pre‑split). The note became convertible on May 4, 2026, the Registration Effective Date, under a Note Modification and Conversion Agreement. Following the transaction, 301,991 shares are reported as indirectly held by NorthView Sponsor I LLC, and 147 shares of Common Stock are reported as held directly. The filing states that Mr. Knechtel, as a manager of NorthView Sponsor I LLC, may be deemed to share beneficial ownership of the LLC-held shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
Profusa, Inc. (PFSA) reported that Chief Executive Officer Jack E. Stover, through NorthView Sponsor I LLC, converted a portion of a Convertible Promissory Note into Common Stock. On August 12, 2026, 1,207,964 shares of Common Stock were issued upon conversion, which became 301,991 shares after a 1-for-4 reverse stock split, at an effective conversion price of $4.28 per share on a post-split basis. The conversion reflected $1,292,521 of note principal converted, and 301,991 indirect shares are reported as held by NorthView Sponsor I LLC, while Stover also holds 73 Common shares directly. Stover may be deemed to share beneficial ownership of the LLC’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Profusa, Inc. (PFSA) reported that large shareholder HRT FINANCIAL LP, identified as a ten percent owner, executed a sale of common stock. On 2026-08-17, HRT FINANCIAL LP sold 18,395 shares of Profusa common stock at $5.94 per share in a sale described as occurring in the open market or a private transaction. Following this transaction, the reporting holder’s direct ownership in Profusa common stock was reported as 0 shares.
Profusa, Inc. (PFSA) had a Form 4 filed by major shareholder HRT Financial LP, a ten percent owner. On August 14, 2026, HRT Financial LP reported selling 3,163 shares of Profusa common stock at $0.902 per share, leaving it with 71,035 shares held directly.
HRT FINANCIAL LP, a more than ten percent owner of Profusa, Inc., reported mixed trading in Profusa common stock. On August 13, 2026, it sold 42,411 shares at $0.888 per share. On August 12, 2026, it purchased 5,585 shares at $0.964 per share. Overall, these transactions represent a net sale of 36,826 shares.
HRT FINANCIAL LP, a ten percent owner of Profusa, Inc., reported mixed trading in the company’s common stock. On 10 August 2026 it purchased 4,016 shares at $0.944 per share, and on 11 August 2026 it sold 2,280 shares at $0.97 per share.
Profusa, Inc. reported insider trading activity by HRT FINANCIAL LP, a ten percent owner of PFSA. Over August 5–7, 2026, the holder executed a mix of open-market trades in common stock, including 926 shares purchased at $0.943 and sales totaling 1,307 shares at prices around $0.94–0.95, resulting in a net reduction of 381 shares. The Rule 10b5-1 plan checkbox was not marked for these transactions.
HRT Financial LP, listed as a ten percent owner of Profusa, Inc., reported open-market purchases of a total of 15,924 shares of common stock on August 3 and 4, 2026, at per-share prices of $0.958 and $0.954. The filing does not mark the Rule 10b5-1 trading plan checkbox.
Profusa, Inc. large shareholder HRT Financial LP, identified as a ten percent owner, reported two non-derivative purchases of Profusa common stock. It bought 8,811 shares at $1.05 per share on July 31, 2026 and 1,063 shares at $1.01 on July 30, 2026, for total reported purchases of 9,874 shares.
Profusa, Inc. reported that major shareholder HRT FINANCIAL LP, a ten percent owner, purchased 1,310 shares of common stock on July 29, 2026 in a purchase classified as a "Purchase in open market or private transaction" at $1.01 per share. Following this trade, HRT FINANCIAL LP directly holds 83,871 shares of Profusa common stock.
STOVER JACK E reported open-market purchase transactions in this Form 4 filing.
Profusa, Inc. director-related entity NorthView Sponsor I LLC converted a Second Amended and Restated Promissory Note with principal of $1,869,796 into 5,342,274 shares of Common Stock. The conversion reflects use of the floor price of $0.35 per share under an April 24, 2026 Note Modification and Conversion Agreement.
Knechtel Fred S. reported open-market purchase transactions in this Form 4 filing.
Profusa, Inc. Chief Financial Officer Fred S. Knechtel reported an indirect transaction involving a Convertible Promissory Note held by NorthView Sponsor I LLC, where he is managing member. The filing states that the entire outstanding principal balance of the Second Amended and Restated Promissory Note of $1,869,796 was converted into 5,342,274 shares of Common Stock at the $0.35 per share floor price.
The conversion price under the note is defined as the greater of 95% of the closing price of the Common Stock on the conversion date and $0.35 per share, pursuant to a Note Modification and Conversion Agreement dated April 24, 2026. The note became convertible on the Registration Effective Date under that agreement. Mr. Knechtel may be deemed to share beneficial ownership of securities held by NorthView Sponsor I LLC but disclaims beneficial ownership except to the extent of his pecuniary interest.
Profusa, Inc. insider filing shows a significant equity distribution to its CFO. On January 26, 2026, Chief Financial Officer Fred S. Knechtel received 818,961 shares of Common Stock and 516,863 warrants to purchase Common Stock at an exercise price of $11.50 per share.
The footnote explains this was a pro rata distribution for no consideration by NorthView Sponsor I LLC to its members, including Knechtel. Following the transaction, he directly beneficially owned 818,961 Common shares and 516,863 warrants, which are exercisable through July 11, 2030.
NorthView Sponsor I, LLC, a 10% owner of Profusa, Inc., reported a pro rata, no‑consideration distribution of its holdings to its members. On January 26, 2026, the Sponsor distributed 4,743,750 shares of Profusa common stock and 5,162,500 warrants to purchase common stock, reducing its reported beneficial ownership of both securities to zero.
Profusa, Inc. director Peter O’Rourke received equity from a sponsor distribution. On 01/26/2026, he was issued 107,750 shares of Common Stock and 15,250 Warrants, both at no consideration, in a pro rata distribution of Profusa securities by NorthView Sponsor I LLC to its members.
Following these transfers, he directly beneficially owns 107,750 Common shares and 15,250 Warrants, each Warrant exercisable for one share of Common Stock.
Profusa, Inc. director Jack E. Stover reported receiving Profusa securities from NorthView Sponsor I LLC through a pro rata distribution. On January 26, 2026, he acquired 553,665 shares of common stock and 380,280 warrants for no consideration.
The warrants relate to 380,280 shares of common stock, carry an exercise price of $11.5 per share, became exercisable on January 26, 2026, and expire on July 11, 2030. After the transaction, Stover directly beneficially owned the same amounts of common stock and warrants reported as acquired.
Profusa, Inc. director Lauren Chung received 30,000 shares of Common Stock on January 26, 2026. The shares were distributed to her for no consideration by NorthView Sponsor I LLC in a pro rata distribution of Profusa securities to the sponsor’s members. Following this transaction, she directly beneficially owns 30,000 Profusa shares.
Profusa, Inc. director Jack E. Stover reported receiving two stock option grants on January 26, 2026. He was awarded options to buy 221,794 shares of common stock at an exercise price of $0.35 per share as an inaugural director award, vesting in three equal annual installments from the business combination closing.
He also received an annual director award of options for 52,866 shares at the same $0.35 exercise price, vesting on the first anniversary of the closing. Both option awards expire on January 26, 2036 and are held directly.
Profusa, Inc. director Rajesh Asarpota received two stock option grants on January 26, 2026. He was awarded options to purchase 221,794 shares of common stock at an exercise price of $0.35 per share as an inaugural director award.
He also received an annual director award of options for 52,866 shares at the same $0.35 exercise price. The inaugural award vests in three equal annual installments over three years from the closing of the business combination between NorthView Acquisition Corp. and Profusa, Inc., while the annual award vests on the first anniversary of that closing.
Profusa, Inc. director Lauren Chung reported receiving stock option awards on January 26, 2026. She was granted options to purchase 221,794 shares of common stock at an exercise price of $0.35 per share as an inaugural director award, vesting in three equal annual installments from the closing of the business combination between NorthView Acquisition Corp. and Profusa.
She also received an additional annual director award of options to purchase 52,866 shares of common stock at the same $0.35 exercise price, which vest on the first anniversary of that closing. Both grants are held directly and reflect standard equity compensation for board service.
Profusa, Inc. director Peter O’Rourke reported two stock option awards on Profusa (PFSA) common stock. On January 26, 2026, he received options for 221,794 shares and a separate award for 52,866 shares, both with a $0.35 exercise price.
The larger grant is an inaugural director award that vests in three equal annual installments over three years from the closing of the business combination between NorthView Acquisition Corp. and Profusa. The second grant is an annual director award vesting on the first anniversary of that closing.